Want to see REVB full AI Analyst Report?
REVB Stock Chart & Stats
$0.90
-$0.04(-6.62%)
At close: 4:00 PM EST
$0.90
-$0.04(-6.62%)
Day’s Range― - ―
52-Week Range$0.88 - $12.88
Previous CloseN/A
Volume326.26K
Average Volume (3M)740.56K
Market Cap
$4.22M
Enterprise Value-$9.17M
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$759.04K
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 07, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.14
Shares Outstanding3,908,420
10 Day Avg. Volume239,834
30 Day Avg. Volume740,557
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-2.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit339.21
Enterprise Value/Ebitda0.91
Forecast
1Y Price Target
$16.00Price Target Upside1677.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger EquityThe balance sheet shows low leverage and a material increase in equity, giving the company more financial flexibility to fund R&D or respond to setbacks. This reduces immediate solvency risk and supports runway extension or financing options over the next several months.
Executive And Governance StabilityRevised multi-year executive contracts with enhanced severance, director election, and auditor ratification strengthen leadership continuity and governance. Stable management and clearer oversight improve execution reliability for clinical programs and fundraising activities over time.
Focused Clinical-stage R&D PipelineA concentrated R&D focus on innate immunity is a structural strength: it targets a sizable, durable therapeutic market and leverages platform science. For a clinical-stage company, success in trials can generate large asymmetric upside and durable franchise value if programs advance.
Bears Say
No RevenueThe company generates no product revenue and reports substantial trailing losses, meaning it cannot self-fund operations. Absent near-term commercialization, continued negative earnings will pressure resources and require external capital to sustain R&D and operations over months.
Persistent Cash BurnConsistent negative operating and free cash flow indicate ongoing cash consumption. Although outflows improved from 2024, the firm remains cash-flow negative and likely dependent on financing, creating dilution and runway risk that can constrain development pacing and strategic choices.
Wide Reverse-split AuthorizationAuthorization of an expansive reverse-split range signals potential capitalization or listing concerns. Use of such authority can alter share structure, deter investors, and suggest latent financing or compliance risks that reflect structural fragility in equity stability and investor confidence.
Revelation Biosciences News
REVB FAQ
What was Revelation Biosciences’s price range in the past 12 months?
Revelation Biosciences lowest stock price was $0.88 and its highest was $12.88 in the past 12 months.
What is Revelation Biosciences’s market cap?
Revelation Biosciences’s market cap is $4.22M.
When is Revelation Biosciences’s upcoming earnings report date?
Revelation Biosciences’s upcoming earnings report date is Aug 07, 2026 which is in 32 days.
How were Revelation Biosciences’s earnings last quarter?
Revelation Biosciences released its earnings results on May 07, 2026. The company reported -$2.71 earnings per share for the quarter, the consensus estimate of -$2.71 by $0.
Is Revelation Biosciences overvalued?
According to Wall Street analysts Revelation Biosciences’s price is currently Undervalued.
Does Revelation Biosciences pay dividends?
Revelation Biosciences does not currently pay dividends.
What is Revelation Biosciences’s EPS estimate?
Revelation Biosciences’s EPS estimate is -0.83.
How many shares outstanding does Revelation Biosciences have?
Revelation Biosciences has 3,908,420 shares outstanding.
What happened to Revelation Biosciences’s price movement after its last earnings report?
Revelation Biosciences reported an EPS of -$2.71 in its last earnings report, expectations of -$2.71. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Revelation Biosciences?
Currently, no hedge funds are holding shares in REVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revelation Biosciences
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
REVB Stock 12 Month Forecast
Average Price Target
$16.00
▲(1677.78% Upside)
Technical Analysis
GT Biopharma
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
8.82% Insiders
0.69% Mutual Funds
10.81% Other Institutional Investors
79.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---